« Previous
Next »
Titles
- Oncology pharmaceuticals: reproductive toxicity testing and labeling recommendations1
- Oncology therapeutic radiopharmaceuticals: nonclinical studies and labeling recommendations1
- One percent of drugs with Medicaid reimbursement were not FDA-approved1
- Opioid use disorder: developing depot buprenorphine products for treatment1
- Orphan drugs: FDA could improve designation review consistency; rare disease drug development challenges continue : report to Congressional requesters1
- Osteoporosis: nonclinical evaluation of drugs intended for treatment1